On April 25, 2018 Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) reported that new interim results from the Company’s ongoing Phase 2a study of cerdulatinib in patients with Non-Hodgkin Lymphoma (NHL), including B-cell NHL and relapsed/refractory peripheral T-cell lymphoma (PTCL), will be presented during a Poster Discussion Session at the 2018 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, June 1-5, in Chicago (Press release, Portola Pharmaceuticals, APR 25, 2018, View Source;p=RssLanding&cat=news&id=2344587 [SID1234525697]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cerdulatinib is an investigational oral, dual SYK/JAK kinase inhibitor that uniquely inhibits two key cell signaling pathways that promote cancer cell growth in certain hematologic malignancies. It is being developed for the treatment of resistant or relapsed hematologic cancer.

Poster Presentation Details:

Presentation Title: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study in Patients with Relapsed/Refractory B- and T-Cell Non-Hodgkin Lymphoma (NHL)

Presenter: Paul A. Hamlin, M.D., Memorial Sloan Kettering Cancer Center

Abstract Number: 7511

Poster Board: 148

Session Title: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia

Date and Time: Monday, June 4, 2018 from 1:15 p.m. – 2:30 p.m. CT

Location: E450, McCormick Place